Laboratory Best Practice Tool
Timely diagnosis of myeloma relies on laboratories performing the correct tests and flagging abnormal results to clinicians. In 2017, the UK National External Quality Assessment Service (UK NEQAS) and Myeloma UK collaborated on a questionnaire which was sent to UK laboratories to assess their practice in relation to diagnosis and monitoring of patients with myeloma.
DetailsMyeloma and AL amyloidosis NICE appraisals: Latest updates
New treatment appraisals continue to come through the Health Technology Appraisal (HTA) pipeline.
Myeloma UK is involved in five active appraisals and one appeal at the National Institute for Healthcare Excellence (NICE).
Myeloma UK partners with UKMS to launch pilot digital infosession for healthcare professionals
Myeloma UK has partnered with the UK Myeloma Society to launch a digital infosession ‘BCMA and GPRC5D Antibodies in Practice: Implementation and management for healthcare professionals’. Find out how to register for free.
DetailsStudy reveals disparities in myeloma diagnosis by race
New research has uncovered a concerning gap in the time taken to diagnose myeloma between ethnic groups, with black people experiencing longer waits for a diagnosis than white people. The study showed that black patients diagnosed with myeloma had a median wait time of over one month longer than white people.
DetailsCSEP Update October 2022: Eight outstanding hospitals awarded Myeloma UK’s CSEP accreditation
We are pleased to report that Royal Hampshire County Hospital, Ipswich Hospital, Belfast City Hospital, The Christie Hospital, HCA UK at University College Hospital, Southmead Hospital, Colchester Hospital and Freeman Hospital have all received Myeloma UK’s Clinical Service Excellence Programme (CSEP) award. Each hospital demonstrated excellent clinical practice with notable highlights.
DetailsKey references
General references for the nurse guide series, and those specific to each guide, are provided for here for further reading.
DetailsMyeloma patients’ experience of COVID-19 and COVID-19 treatments
To inform a NICE appraisal Myeloma UK worked with Blood Cancer UK, Leukaemia Care and Anthony Nolan to survey myeloma and other blood cancer patients about their experiences of COVID-19 and COVID-19 treatment.
DetailsMyeloma UK’s new Peer Buddy service helps patients live with incurable cancer
In February 2022 Myeloma UK launched a new Peer Buddy service to connect and empower myeloma patients and their loved ones.
Feedback from service users demonstrates the significant improvement support from someone with experience of the same condition has on wellbeing.